Stock listing
Glyconex, Inc.
Selected listing: 4168 · TPEX · TWD · TW
Glyconex, Inc. (TPEx:4168), Health Technology. Latest release Apr 14, 2026: GlycoNex Receives PMDA Approval in Japan to Initiate First-in-Human Phase 1 Trial…
- Ticker
- TPEx:4168
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- TPEx
- Currency
- TWD
About Glyconex, Inc.
Glyconex, Inc. is a public company listed under the ticker 4168 on the Taiwan market. Glyconex focuses on developing innovative solutions in its industry, contributing to advancements and growth within its sector.
Latest news from Glyconex, Inc.
GlycoNex Receives PMDA Approval in Japan to Initiate First-in-Human Phase 1 Trial of GNX1021 in Gastrointestinal Cancers
April 14, 2026
GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC
March 23, 2026
GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program
December 8, 2025
GlycoNex and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer
November 24, 2025
GlycoNex Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis
October 29, 2025